Publicly Funded, Pegylated Interferon-Alpha Treatment in British Columbia: Disparities in Treatment Patterns for People with Hepatitis C | Zendy

Priscilla C. Hsu | Zendy; Jane A. Buxton | Zendy; Andrew W. Tu | Zendy; Warren D. Hill | Zendy; Amanda Yu | Zendy; Mel Krajden | Zendy

Open Access

Publicly Funded, Pegylated Interferon-Alpha Treatment in British Columbia: Disparities in Treatment Patterns for People with Hepatitis C

Author(s) -

Priscilla C. Hsu,

Jane A. Buxton,

Andrew W. Tu,

Warren D. Hill,

Amanda Yu,

Mel Krajden

Publication year - 2008

Publication title -

canadian journal of gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 1916-7237

pISSN - 0835-7900

DOI - 10.1155/2008/243607

Subject(s) - medicine , hepatocellular carcinoma , cirrhosis , pegylated interferon , hepatitis c , hepatitis c virus , liver disease , chronic hepatitis , demography , immunology , virus , ribavirin , sociology

An estimated 60,000 British Columbians are chronically infected with the hepatitis C virus (HCV); 10% to 20% will develop cirrhosis after 20 years and 5% to 10% of these will develop hepatocellular carcinoma. Although treatment may prevent cirrhosis and liver cancer, and improve quality of life, availability is limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research